Evidence map›Paper›PMID 41560346›Full record

ArticleAmerican journal of men's health

Efficacies of Single-Dose Ceftriaxone Regimens in Treating Gonococcal Paraurethral Duct Infection in Men.

Wenge Fan, Qingsong Zhang, Mei Wei, Yuan Zhu

Abstract read
In one paragraph

Article in American journal of men's health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wenge FanDepartment of Dermatology, First People's Hospital of Changshu City, Changshu Hospital Affiliated to Soochow University, Changshu, China.ORCID 0000-0001-5597-4417
Qingsong ZhangDepartment of Dermatology, Nantong University Affiliated Qidong Hospital, Qidong, China.
Mei WeiDepartment of Dermatology, First People's Hospital of Changshu City, Changshu Hospital Affiliated to Soochow University, Changshu, China.
Yuan ZhuDepartment of Dermatology, First People's Hospital of Changshu City, Changshu Hospital Affiliated to Soochow University, Changshu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study compared the efficacies of single-dose ceftriaxone therapy at doses of 250 mg, 500 mg, and 1 g for gonococcal paraurethral duct infection in men. Forty-eight men with gonococcal paraurethral duct infection were assigned to Groups A, B, and C based on their order of arrival in the clinic; each group comprised 16 patients. Groups A, B, and C received single intramuscular doses of ceftriaxone at 250 mg, 500 mg, and 1 g, respectively. The mean times to resolution of purulent discharge from the paraurethral duct were 1.87 ± 0.81 days in Group A, 1.06 ± 0.25 days in Group B, and 1.13 ± 0.34 days in Group C. The mean times to resolution of erythematous swelling at skin lesions were 4.75 ± 1.69 days in Group A, 3.44 ± 0.89 days in Group B, and 3.31 ± 1.25 days in Group C. The mean times to resolution of tenderness at skin lesions were 5.25 ± 1.00 days in Group A, 3.06 ± 0.10 days in Group B, and 2.38 ± 1.03 days in Group C. The mean times to closure of the paraurethral duct orifice were 9.88 ± 2.92 days in Group A, 6.88 ± 1.71 days in Group B, and 6.38 ± 1.86 days in Group C. The resolution times significantly differed between Group A and Groups B and C (all

Indexed as

Anti-Bacterial AgentsCeftriaxoneGonorrheaAdultDose-Response Relationship, DrugHumansInjections, IntramuscularMaleMiddle AgedNeisseria gonorrhoeaeTreatment OutcomeUrethraYoung AdultAnti-Bacterial AgentsCeftriaxoneceftriaxonegonorrhoeaeparaurethral ducttreatment

Identifiers

PMID41560346
PMCPMC12827929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.